PROCEPT BioRobotics to Report First Quarter 2023 Financial Results on April 27, 2023 and Present at the Bank of America 2023 Health Care Conference in Las Vegas
06 4월 2023 - 5:03AM
PROCEPT® BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a
surgical robotics company focused on advancing patient care by
developing transformative solutions in urology, today announced it
will report financial results for the first quarter of 2023 before
market open on Thursday, April 27, 2023. The Company’s management
will host a corresponding conference call beginning at 8:00 a.m.
Eastern Time.
Investors interested in listening to the conference call may do
so by following one of the below links:
- Webcast link for interested listeners:
- https://edge.media-server.com/mmc/p/qk7hrxz5
- Dial-in registration for sell-side research analysts:
-
https://register.vevent.com/register/BIadc240895f944ef3b7f80601d78f317c
Members of management will also be presenting at the upcoming
Bank of America 2023 Health Care Conference in Las Vegas.
Management is scheduled to present on Wednesday, May 10 at 4:20
p.m. Pacific Time.
Live audio of each webcast will be available on the “Investors”
section of the Company’s website at:
https://ir.procept-biorobotics.com.
Archived recordings will be available on the “Investors” section
of the Company’s website at: https://ir.procept-biorobotics.com.
Each webcast will be available for replay for at least 90 days
after the event.
About PROCEPT BioRobotics CorporationPROCEPT
BioRobotics is a surgical robotics company focused on advancing
patient care by developing transformative solutions in urology.
PROCEPT BioRobotics develops, manufactures and sells the AquaBeam
Robotic System, an advanced, image-guided, surgical robotic system
for use in minimally invasive urologic surgery with an initial
focus on treating benign prostatic hyperplasia, or BPH. BPH is the
most common prostate disease and impacts approximately 40 million
men in the United States. PROCEPT BioRobotics designed Aquablation
therapy to deliver effective, safe and durable outcomes for males
suffering from lower urinary tract symptoms, or LUTS, due to BPH
that are independent of prostate size and shape or surgeon
experience. The Company has developed a significant and growing
body of clinical evidence, which includes nine clinical studies and
over 150 peer-reviewed publications, supporting the benefits and
clinical advantages of Aquablation therapy.
Investor Contact:Matt Bacso, CFAVP, Investor
Relations and Business
Operationsm.bacso@PROCEPT-BioRobotics.com
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024